Clinical trial NCT06995131: Evaluation of Aqueous Humor DEL-1 and IL-17 Levels in Diabetic Cataract Patients
Official title: Evaluation of Aqueous Humor DEL-1 and IL-17 Levels in Diabetic Cataract Patients
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Diabetic Group (n=30)
Non-diabetic Group
Keywords: Diabetes Mellitus
cataract
aqueous humor
Del 1
IL17
Lead sponsor: Uşak University
Sponsor class: OTHER
First posted: 2025-05-29
Enrollment: 60
Sex: ALL
Minimum age (years): 50
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: SCREENING

Brief summary: By comparing DEL-1 and IL-17 levels in the aqueous humor of diabetic cataract patients with the aqueous humor of non-diabetic patients, we aim to understand the biochemical effects of diabetes-related inflammatory processes in the eye.

Detailed description: Developmental Endothelial Locus-1 (DEL-1) is a molecule related to endothelial cells and is a protein involved in intercellular interactions. It is generally associated with the development and function of endothelial cells lining the inner surface of the vessel. It plays an important role in the regulation of inflammation, the development of vessels and the organization of endothelial cells. It has also been shown to be associated with some types of cancer. It may also be effective in tissue regeneration and healing of injuries.

IL-17 (Interleukin-17) is a group of cytokines that play an important role in the immune system. There are several subtypes of IL-17, the best known and most researched being IL-17A. It regulates the body's immune response to certain infections. It is an important cytokine that initiates and supports the inflammation process. IL-17 plays an important role in the pathogenesis of various autoimmune and inflammatory diseases.

DEL-1 and IL-17 are two different molecules that act on inflammation and immune responses. DEL-1 helps regulate inflammation by protecting vascular health, while IL-17 can accelerate the course of diseases by increasing inflammation.

Diabetes is a systemic disease associated with oxidative stress and chronic inflammation. Retinopathy, cataract and glaucoma diseases develop due to diabetes. DEL-1 is a protein involved in the maintenance of vascular homeostasis and regulation of inflammation. Since diabetic patients have chronic inflammation and microvascular dysfunction, changes in DEL-1 levels may provide important clues to the pathophysiology

Eligibility criteria: Inclusion Criteria:

* Cataract diagnosed and surgery planned
* Patients without any other ocular pathology other than cataract.
* Type 2 DM for at least 5 years in the diabetic group

Exclusion Criteria:

* Patients with previous intraocular surgery
* Those with inflammatory eye diseases (e.g. uveitis)
* Those with autoimmune diseases or systemic inflammatory diseases
* Those receiving local or systemic steroid therapy
* Those with severe systemic disease (e.g. advanced renal failure, malignancy)

Primary outcomes:
measure: DEL-1 and IL-17 levels
timeFrame: Perioperative
Secondary outcomes:
measure: Correlation between DEL-1 and IL-17
timeFrame: Perioperative
measure: Association of biomarker levels with HbA1c
timeFrame: Perioperative
measure: Impact of demographic factors
timeFrame: Baseline
Other outcomes:
Locations:
city: Uşak
country: Turkey
facility: Uşak Training and Research Hospital
Study officials:
References: